Galectin-3 (Mr 35,000) is a galactose/lactose-specific lectin found in association with ribonucleoprotein complexes in many animal cells. Cell-free-splicing assays have been carried out to study the requirement for galectin-3 in RNA processing by HeLa cell nuclear extracts by using 32P-labeled MINX as the pre-mRNA substrate. Addition of saccharides that bind galectin-3 with high affinity inhibited product formation in the splicing assay, while addition of carbohydrates that do not bind to the lectin did not inhibit product formation. Nuclear extracts depleted ofgalectin-3 by affinity adsorption on a lactoseagarose column were deficient in splicing activity. Extracts subjected to parallel adsorption on control celiobiose-agarose retained splicing activity. The activity of the galectin-3-depleted extract could be reconstituted by the addition of purified recombinant galectin-3, whereas the addition of other lectins, either with a similar saccharide binding specificity (soybean agglutinin) or with a different specificity (wheat germ agglutinin), did not restore splicing activity. The formation of splicing complexes was also sensitive to galectin-3 depletion and reconstitution. Together, these results define a requirement for galectin-3 in pre-mRNA splicing and identify it as a splicing factor.
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Galectin-3 (1) is the name for the galactose(Gal)/lactose (Lac)-specific lectin previously known under a number of different designations, including carbohydrate binding protein 35 (CBP35) (2), Mac-2 (3), IgE-binding protein (4), CBP30 (5), L-29 (6) , and L-34 (7) . In this communication, we will use the designation galectin-3 when we refer to the gene or protein in general, assuming that studies carried out on the gene or protein under any one of the above names is applicable to all of them. There are instances, however, in which the specific molecule used by one laboratory is slightly (but significantly) different from the corresponding molecule of another laboratory-e.g., the cDNAs reported for murine CBP35, Mac-2, and L-34 are of different lengths. In this case, we will use the old designation to highlight the specific source of the molecule.
The galectin family of animal lectins is distinguished by the Gal/Lac specificity of its carbohydrate recognition domain (CRD), with highly conserved residues between members of the family (galectin-1, -2, -3, and -4) and between the homologs found in various species for any given single member (for reviews see refs. 8 and 9) . The polypeptide of galectin-3 is delineated into two domains (2, 8) : an N-terminal half that is proline and glycine rich, with limited similarity to proteins of the heterogeneous nuclear ribonucleoprotein (RNP) complexes, and a C-terminal half that is similar to the CRD of other members of the galectin family. The majority of galectin-3 is found in the cytoplasm and nucleus of mouse 3T3 fibroblasts in the form of RNP complexes (10, 11) . For example, treatment of permeabilized cells with ribonuclease A released the lectin from the nucleus with concomitant loss of immunofluorescent staining. Two isoelectric variants of galectin-3 have been identified: a phosphorylated (pl 8.2) form and a nonphosphorylated (pl 8.7) form (12) . The phosphorylated species is found in both the nucleus and cytoplasm, whereas the nonphosphorylated form localizes exclusively in the nucleus.
Nuclear extracts (NEs) prepared from HeLa cells and capable of carrying out pre-mRNA splicing contain galectin-3. On the basis of preliminary experiments that showed that saccharide ligands with high affinity for galectin-3 can perturb the splicing reaction, we sought conditions to deplete galectin-3 from NEs. We now report that extracts depleted of galectin-3 do not support spliceosome formation or premRNA splicing. The galectin-3-depleted extracts, however, regain splicing activity upon reconstitution with the recombinant lectin purified from an Escherichia coli expression system.
MATERIALS AND METHODS
Preparation of NEs and Their Depletion and Reconstitution. NEs were prepared from HeLa S3 suspension cultures in buffer D [20 mM Hepes, pH 7.9/20% (vol/vol) glycerol/0.1 M KCl/0.2 mM EDTA/0.5 mM phenylmethylsulfonyl fluoride (PMSF)/0.5 mM dithiothreitol] as described (13) . Typically, NEs with protein concentrations of approximately 18-22 mg/ml were prepared and stored as frozen aliquots at -80°C.
Protein concentrations were determined by the Bradford assay (ref. 14; Bio-Rad).
NEs were depleted of CBPs by binding them to a-Lac insolubilized on 6% beaded agarose (LAC-A), purchased from Sigma. Agarose derivatized with cellobiose (CELLO-A) was used as a control for NE depletion. A volume of 200-250 p,l of packed agarose was washed with 20 vol of wash buffer (20 mM Hepes, pH 7.9/0.5 M NaCl) in disposable columns (Pierce). NEs were preincubated in buffer 1 (buffer 1 = 60% buffer D) containing 2.5 mM MgCl2, 1 mM ATP, and 5 mM creatine phosphate in a volume of 50 ,ul for 30 min at 30°C. NaCl was then added to a final concentration of 0.5 M. Preincubated NEs were then added to the washed saccharideagarose and incubated for 30 min at 4°C with rotation. The unbound fraction was removed from the column. The matrices were next washed with 50 ,ul of buffer 1 containing 0.5 M NaCl, and this wash was added to the unbound fraction. The matrices were washed with 10 vol ofwash buffer, and the bound material was eluted by boiling the samples in 200 ,ul of Laemmli sample buffer (15) . Aliquots (20 p,l) of nondepleted NE and the unbound fractions of the saccharide-adsorption procedure were dialyzed in a microdialyzer (Pierce) for 40 min against buffer 1.
In reconstitution experiments, recombinant CBP35 (rCBP35) (16) The intensities of the bands on the gels were quantitated by direct 13-particle counting by using an AMBIS Systems system. The percent product formation (ligated exon 1-exon 2) was calculated by dividing the radioactivity present in the final product by the total radioactivity present in the pre-mRNA substrate (exon 1-intron-exon 2), the splicing intermediates (exon 2-lariat, excised lariat, exon 1), and the product at the end of the incubation.
Gel Mobility-Shift Assay for Splicing Complex Formation. The formation of splicing complexes was monitored by native gel electrophoresis (17, 18) . Splicing reaction mixtures (10 ,ul) were incubated at 30°C for 15-20 min. Heparin was added (final concentration 0.6 mg/ml), and the mixtures were incubated at 30°C for 15 min. Before electrophoresis, 1 ,ul of glycerol (containing 0.2% each of bromphenol blue, xylene cyanole, and phenol red) was added to each sample. The samples were loaded onto a prerun polyacrylamide gel [bisacrylamide/acrylamide, 1:80 (wt/wt)], and electrophoresis was carried out in 0.5 M Tris base/0.5 M glycine, pH 8.8, at 4°C and 25 V/cm for 105 min. The migration of splicing complexes was determined by autoradiography.
Western Blot Analysis. SDS/polyacrylamide gel electrophoresis was carried out in 12% acrylamide gels (15) . The separated components were transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad) in 25 mM Tris/193 mM glycine/20% methanol. After protein transfer, the membranes were incubated with 5% nonfat dry milk dissolved in phosphate-buffered saline (PBS; 10 mM sodium phosphate/ 150 mM NaCl, pH 7.2) containing 0.05% Tween 20 (PBS-T). Galectin-3 was detected on the membranes by using the rat monoclonal antibody anti-Mac 2 (19) . Incubation with the primary antibody (freshly diluted 1:5000 in 5% nonfat dry milk in PBS-T) was carried out at room temperature for 2 h, followed by five washes in PBS-T for 15 min each. The membranes were incubated with horseradish peroxidaseconjugated goat anti-rat antibodies (Pierce) diluted 1:3000 in PBS-T for 30 min at room temperature and washed five times for 15 min each in PBS-T. The products of the horseradish peroxidase reaction were revealed with the enhanced chemiluminescence reagents from Amersham by following the manufacturer's protocol. RESULTS Effect of Saccharides on Pre-mRNA Splicing. The cell-free assay for the splicing of pre-mRNA by HeLa cell NEs was optimized for the MINX substrate. In a typical assay (final protein concentration 10 mg/ml), approximately 20-30% of the input substrate was converted to product (Fig. 1, lane 1) . This conversion showed a stringent requirement for ATP (Fig.  1, lane 2) . When the NE was preincubated with various saccharides (75 mM) prior to the addition of the pre-mRNA substrate, inhibition of product formation was observed for Lac (Fig. 1, lane 8) , TDG (Fig. 1, lane 4) , and melibiose (data not shown). Other mono-and disaccharides that were tested, as well as the noncarbohydrate inositol, failed to show inhibition of product formation.
The effect of the inhibitory saccharides was concentration dependent; half-maximal inhibition was observed at <50 mM for TDG and Lac (Fig. 1, lanes 3-6 and lanes 7-10, respectively) . Both of these saccharides bind to galectin-3 (20) with approximately the same hierarchy of affinities as that seen in the inhibition of splicing. The disaccharide cellobiose (Fig. 1 , lanes 15-18) and the monosaccharide Gal (Fig. 1, lanes 11-14) did not show an effect on the cell-free-splicing assay. Although Gal is a saccharide ligand for the galectin family of lectins, its affinity for binding galectin-3 is about two orders of magnitude lower than the affinity of Lac for galectin-3 (20) . Thus, the inhibitory versus noninhibitory saccharides observed in the splicing assay correlate with the relative order of their binding affinities for galectin-3.
The inhibitory effects of Lac and TDG were neither extract nor pre-mRNA substrate restricted. NEs prepared from HeLa cells over the course of 2 years were sensitive to inhibition by these saccharides. In addition, similar splicing inhibition was observed with human 13-globin pre-mRNA (21) and another recombinant adenovirus transcript, pRSP-1 (22) . For example, Proc. Natt Acad ScL USA 92 (1995) ..'. a human serum albumin conjugate containing 14 covalently linked blood group A-tetrasaccharide moieties completely inhibited the splicing of the 3-globin substrate at a concentration as low as 170 ,M, while a parallel serum albumin control yielded no effect. Blood group A-tetrasaccharide has been shown to exhibit significantly greater affinity for galectin-3 than simple mono-and disaccharide ligands (20, 23) . All of these results suggest that certain saccharides can perturb cell-free splicing, possibly by binding to galectin-3 in the NE.
Splicing Activity of Galectin-3-Depleted Extracts. To test for a role of nuclear galectin-3 in pre-mRNA splicing, we used saccharide-affinity adsorption to deplete the protein from NEs. NEs were pretreated with 0.5 M NaCl to dissociate splicing or RNP complexes and then incubated with LAC-A. Parallel experiments were carried out on CELLO-A as a control matrix. To monitor the extent of galectin-3 depletion, the levels of galectin-3 in the original NE and in the unbound and bound fractions of the saccharide adsorptions were quantitated by using the galectin-3-specific monoclonal antibody anti-Mac-2 (3, 19) . A comparison of the unbound and bound fractions showed that LAC-A removed >95% of galectin-3 ( Fig. 2A, lanes 1 and 2) . Control CELLO-A removed <5% of galectin-3 ( Fig. 2A, lanes 3 and 4) . Protein determinations revealed that the depletion procedure also decreased the total protein content of the unbound fractions by about 25%, compared with the nontreated NEs. Thus, when the saccharide-affinity-depleted extracts were tested in splicing assays, the nondepleted extracts were diluted appropriately for comparison. The unbound fraction of the LAC-A adsorption, depleted of galectin-3, exhibited little or no splicing activity (Fig. 2B, lane  3) compared with the corresponding fraction of the CELLO-A adsorption (Fig. 2B, lane 4) or to the original untreated NE (Fig. 2B, lane 2) . CELLO-A-depleted extracts showed no change in splicing activity. Thus, the removal of galectin-3 from NEs resulted in a complete loss of splicing activity.
Reconstitution of Splicing in Galectin-3-Depleted Extracts. We had previously described the production of a recombinant galectin-3 by using an E. coli expression system for the cloned cDNA for CBP35 (16) . The availability of rCBP35 provided the opportunity to test whether splicing activity in the unbound fraction of NEs after LAC-A adsorption can be recovered by addition of a single, purified protein. Indeed, the addition of rCBP35 restored splicing activity to the galectin-3-depleted extract (Fig. 3, lanes 1 and 2) . In contrast, the plant lectin soybean agglutinin, with a saccharide-binding specificity (24) similar to that of galectin-3, was unable to reconstitute splicing activity (Fig. 3, lane 3) . Similarly, wheat germ agglutinin, which binds to glycoconjugates containing sialic acids or N-acetyl-D-glucosamine (24) , also failed to restore splicing activity to the galectin-3-depleted extract (data not shown). Finally, neither rCBP35 (Fig. 3, lane 4 ) nor soybean agglutinin (data not shown) had an effect on the splicing assay when added to a nondepleted NE.
The restoration of splicing activity by rCBP35 to the unbound fraction of the LAC-A-adsorbed NE was dependent on the amount of recombinant protein added. Addition of 0.5 Ag of rCBP35 did not restore activity (Fig. 4A, lane 2) , whereas 1-4 ,ug of rCBP35 did restore activity (Fig. 4A, lanes 3-5) . Surprisingly, addition of 8 ,ug of rCBP35 resulted in no splicing activity (Fig. 4A, lane 6) . The amount of rCBP35 added in the reconstitution experiments should be put in the context of the total protein content in a reconstituted splicing reaction mixture (-60 ,g) and of galectin-3 (0.5-1 ng) in an equivalent splicing reaction mixture containing nondepleted NE. The . r v i z 2 3 4 S X ? X ? e 2 2 , . . r ? ? : ? maximal extent of reconstituted splicing activity represented >70% of the activity of nondepleted NE. More important, galectin-3-depleted extracts reconstituted with rCBP35 showed inhibition of splicing upon addition of TDG, as was observed with the original NE (Fig. 4A, lane 7) .
Analysis of Spliceosome Complex Formation in Original, Depleted, and Reconstituted Extracts. The MINX pre-mRNA forms several complexes during the course of the splicing reaction, as revealed by gel mobility-shift assays of the 32p-labeled substrate in nondenaturing gels (17) . The first complex formed is an ATP-independent complex designated as the H complex. The addition of ATP results in the association of Ul and U2 small nuclear RNPs, forming the A and A' complexes, respectively. This, in turn, is followed by the association of U4, U5, and U6 small nuclear RNPs to yield the B complex.
When NEs were depleted of galectin-3 by LAC-A adsorption, the formation of virtually all of the ATP-dependent splicing complexes was inhibited (Fig. 4B, compare lanes 1 and  7) . NEs subjected to adsorption on CELLO-A retained the ability to form ATP-dependent complexes (data not shown). As expected, galectin-3-depleted extracts reconstituted with rCBP35 regained the ability to form splicing complexes (Fig.  4B, lanes 3-5) . As was observed in assays of pre-mRNA splicing activity, the addition of 0.5 or 8 ,ug of rCBP35 did not reconstitute spliceosome assembly (Fig. 4B, lanes 2 and 6,  respectively) . All of these results suggest that galectin-3 may play a role in the initial assembly of the complexes required for splicing.
DISCUSSION
The key findings documented in the present study include the following: (i) NE capable of carrying out pre-mRNA splicing contains galectin-3, a Gal/Lac-specific lectin found in both the cytoplasmic and nuclear fractions of cells; (ii) saccharide ligands that bind to galectin-3 inhibit splicing; (iii) NE depleted of galectin-3 by affinity adsorption on LAC-A fails to form spliceosomal complexes with pre-mRNA and does not carry out the in vitro splicing reaction; and (iv) the activities of the galectin-3-depleted extract, in forming splicing complexes and in performing the pre-mRNA processing reaction, can be reconstituted by the addition of recombinant galectin-3 purified from an E. coli expression system. On the basis of these results, we believe we have identified another RNA splicing factor.
Crucial to our conclusion are the experiments involving the restoration of the splicing activities of galectin-3-depleted extracts with the addition of rCBP35. Reconstitution of splicing by rCBP35 required significantly more galectin-3 than that found in an equivalent amount of nondepleted extract. This could be due to several factors. First, endogenous nuclear galectin-3 exists in both phosphorylated and unphosphorylated forms (12) . The rCBP35 expressed in E. coli would not be subject to posttranslational modifications such as phosphorylation. Perhaps the phosphorylated form is required for splicing activity, and such phosphorylation may be ratelimiting or inefficient in HeLa cell nuclear extracts. Second, rCBP35 produced in the expression vector for secretion out of E. coli (16) contains three extra amino acids (Ala-Glu-Phe) on the N terminus of the mature protein. This extension may alter in a subtle manner the three-dimensional configuration of the protein and diminish its activity. Third, the amount or nature of the nuclear ligand for galectin-3 may be altered during the extensive dissociation, depletion, and reconstitution procedures. Proteolysis or deglycosylation of the ligand are two possible events in this regard. Finally, rCBP35 may require more time to assemble into a splicing-competent complex than was allowed by the experimental conditions we used.
The nuclear component that interacts with galectin-3 has not yet been identified. Three classes of candidates are formally possible. First, galectin-3 may interact via its CRD with a Lac-containing nuclear glycoprotein. Nuclear proteins known to be glycosylated include nucleoporins, transcription factors AP-1, Sp-1, CTF/NF-1, AP-2, and AP-4 (25, 26) , and RNA polymerase II (27) . It has been suggested, although not rigorously proven, that the high mobility group proteins, HMG 1, 2, 14, and 17 contain N-linked complex oligosaccharides (28, 29) with Gal as one of the constituents (30) . With the exception of the HMGs, these nuclear glycoproteins contain only 0-linked N-acetyl-D-glucosamine, a carbohydrate that has no detectable affinity for galectin-3. It should be noted that none of these nuclear components has been shown to have a role in splicing, nor have any of the known splicing factors been characterized as glycoproteins. However, an N-acetyl-Dglucosamine-bearing glycoprotein (Mr 43,000) has been shown to coprecipitate with heterogeneous nuclear RNP (hnRNP) C proteins and is thought to be a component of the hnRNP complex (31) . There is increasing evidence that hnRNP proteins Al, C1/C2, and I/PTP contribute to the efficiency or the regulation of splicing (reviewed in ref. 32 ). It would be interesting to determine whether the 43-kDa glycoprotein can be added to the growing list of hnRNP proteins involved in RNA processing. Second, the CRD domain of galectin-3 may interact with a nonglycosylated nuclear polypeptide containing a structure mimicking Lac. For example, peptides that bind to the lectin concanavalin A with dissociation constants equivalent to mannose, the saccharide ligand for the lectin, have been isolated from random hexapeptide libraries (33, 34 (Fig. 1, lanes 3 and 7) , product formation is inhibited approximately 80%, whereas exon 2-lariat and exon 1 intermediates are reduced by only 5-10% compared with a nontreated extract. This disparity between inhibition of exon ligation versus the first cleavage event is maintained at the higher concentrations of Lac and TDG tested. Perhaps the interaction of galectin-3 with a splicing factor is sufficiently avid or occurs via the CRD of the galectin so that free ligand cannot act as an effective competitor. As other splicing components enter the active complex, the CRD may become accessible to Lac. The binding of Lac (i) may prevent galectin-3 from binding to its partner and stop further splicing events or (ii) may alter the conformation of galectin-3 so that subsequent splicing steps are blocked. On the basis of differential scanning calorimetry studies, a conformational change in galectin-3 has been demonstrated upon Lac binding (16) . Data from depletion experiments can be interpreted to support this model. In this case, removal of galectin-3 results in a dramatic reduction in spliceosomal complexes without a discernible effect on the formation of the H complex. This suggests that galectin-3 is required for assembly of the initial A complex.
A final possibility for the mode of action of galectin-3 is the binding to a general inhibitor of splicing. Upon depletion of galectin-3 or its inactivation-e.g., via carbohydrate bindingthe general inhibitor would suppress the processing of the pre-mRNA substrate. This notion is formally distinguished from the other possibilities because it would not require galectin-3 to be present in the splicing complexes.
Finally, it should be noted that if other members of the galectin family are found in NE, they will also be removed by LAC-A adsorption. We have identified, by Western analysis, galectin-1 (previously designated L-14) in the bound fraction of LAC-A (S.D., unpublished observations). However, rCBP35 alone can reconstitute splicing activity to LAC-Aadsorbed extracts. Thus, it is possible that galectin-1 or other nuclear galectins are not splicing factors, perhaps because they contain only the CRD but not the proline-and glycine-rich domain found in galectin-3. Alternatively, all nuclear galectins may be splicing factors, but their mode of action in splicing can be assumed by any one galectin, hinting at a functional redundancy.
